News in the Life Sciences Industry

GAITHERSBURG, Md. and GUANGZHOU, China, Jan. 24, 2020 /PRNewswire/ -- Sirnaomics Inc. ("Sirnaomics"), a leading biopharmaceutical company in discovery and development of novel RNAi therapeutics, announced today that it has mobilized its research teams both in USA and China to develop novel RNAi-based... Read more ››

DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The Read more ››

DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The Read more ››

INDIANAPOLIS, Jan. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Anat Hakim will join the company on February 3, 2020 as senior vice-president and general counsel. Hakim succeeds Michael J. Harrington who will retire on January 31, 2020.

CHICAGO, Jan. 24, 2020 /PRNewswire/ -- Hillrom (NYSE: HRC), today announced financial results for its fiscal first quarter ended December 31, 2019, confirmed its fiscal 2020 revenue guidance and raised the bottom of its adjusted earnings per diluted share guidance range.

DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The Read more ››

SALT LAKE CITY, Jan. 24, 2020 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the receipt of formal acceptance from the U.S. Food and Drug Administration (FDA) to proceed with its CNM-Au8 as one of the first three drug regimens in the HEALEY... Read more ››

DALLAS, Jan. 24, 2020 /PRNewswire/ -- Leader in advanced aesthetic solutions, Crown Aesthetics, a division of Crown Laboratories, Inc., is proud to announce the launch of ProGen PRP(TM) Advantage, an easy to use, single spin system that features 15ml and 30ml tubes, yielding... Read more ››

BAUDETTE, Minn., Jan. 24, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Tolterodine Extended-Release Capsules, 2 mg and 4 mg. The current annual U.S. market for this product is approximately $101 million, according to IQVIA.

SUZHOU, China, Jan. 24, 2020 /PRNewswire/ --CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient in Australia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with regorafenib,... Read more ››

SUZHOU, China, Jan. 24, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) announced that it successfully hosted its 2020 U.S. R&D Day in New York on January 21. CStone's management team highlighted major milestones the Company had achieved in research, clinical... Read more ››